Variable | Treatment outcome [n (%)] | Odds of treatment success versus failure, loss to follow-up, or death [aOR (95% CI)] | p-value | |
---|---|---|---|---|
Success (n = 401) | Failure, loss to follow-up, or death (n = 211) | |||
Age | n/aa | n/aa | 0.99 (0.98–1.00) | 0.079 |
Gender | ||||
Female | 112 (75.7%) | 36 (24.3%) | 1.00 (reference) | 0.016 |
Male | 289 (62.3%) | 175 (37.7%) | 0.56 (0.34–0.90) | |
Diabetes | ||||
No | 315 (67.5%) | 152 (32.5%) | 1.00 (reference) | 0.286 |
Yes | 86 (59.3%) | 59 (40.7%) | 0.72 (0.40–1.32) | |
Heart disease | ||||
No | 339 (66.7%) | 169 (33.3%) | 1.00 (reference) | 0.683 |
Yes | 62 (59.6%) | 42 (40.4%) | 0.83 (0.33–2.05) | |
HIV | ||||
No | 377 (67.0%) | 183 (33.0%) | 1.00 (reference) | 0.049 |
Yes | 24 (46.2%) | 28 (53.8%) | 0.44 (0.20–1.00) | |
Respiratory disorderb | ||||
No | 337 (67.0%) | 166 (33.0%) | 1.00 (reference) | 0.395 |
Yes | 64 (58.7%) | 45 (41.3%) | 0.76 (0.41–1.42) | |
Substance abuse | ||||
No | 339 (66.9%) | 168 (33.1%) | 1.00 (reference) | 0.607 |
Yes | 62 (59.0%) | 43 (41.0%) | 0.77 (0.29–2.09) | |
Antibiotic resistance | ||||
RR/MDR-TBc | 331 (68.0%) | 156 (32.0%) | 1.00 (reference) | 0.039 |
Pre-XDR or XDR-TBd | 70 (56.0%) | 55 (44.0%) | 0.53 (0.29–0.97) | |
Initial sputum (smear) positivity | ||||
No | 155 (69.2%) | 69 (30.8%) | 1.00 (reference) | 0.429 |
Yes | 246 (63.4%) | 142 (36.6%) | 0.85 (0.57–1.27) | |
Smear conversion after 2 months | ||||
No | 45 (50.0%) | 45 (50.0%) | 1.00 (reference) | 0.204 |
Yes | 356 (68.2%) | 166 (31.8%) | 1.47 (0.81–2.67) | |
Culture conversion after 2 months | ||||
No | 85 (58.2%) | 61 (41.8%) | 1.00 (reference) | 0.361 |
Yes | 316 (67.8%) | 150 (32.2%) | 1.28 (0.75–2.20) | |
Smear conversion after 4 months | ||||
No | 12 (34.2%) | 23 (65.8%) | 1.00 (reference) | 0.106 |
Yes | 389 (67.4%) | 188 (32.6%) | 2.47 (0.82–7.39) | |
Culture conversion after 4 months | ||||
No | 22 (42.3%) | 30 (57.7%) | 1.00 (reference) | 0.008 |
Yes | 379 (67.7%) | 181 (32.3%) | 2.93 (1.33–6.45) | |
At least one side effect experienced during inpatient treatment | ||||
No | 336 (66.8%) | 167 (33.2%) | 1.00 (reference) | 0.645 |
Yes | 65 (59.6%) | 44 (40.4%) | 0.80 (0.32–2.05) | |
At least one side effect experienced during outpatient treatment | ||||
No | 319 (64.2%) | 178 (35.8%) | 1.00 (reference) | 0.104 |
Yes | 82 (71.3%) | 33 (28.7%) | 1.54 (0.91–2.61) |